A Phase III, randomized, two armed, parallel, double blind, active controlled, equivalency clinical trial to determine the therapeutic efficacy and safety between Cetuximab (produced by CinnaGen) and FOLFIRI compared with Erbitux (Cetuximab, the reference drug, produced by Merck Company) and FOLFIRI as first-line treatment for RAS wild-type Metastatic Colorectal Cancer
Phase of Trial: Phase III
Latest Information Update: 29 May 2019
Price : $35 *
At a glance
- Drugs Cetuximab (Primary) ; Fluorouracil; Folinic acid; Irinotecan
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- Sponsors CinnaGen
- 31 Aug 2018 Biomarkers information updated
- 13 Feb 2018 Planned End Date changed from 22 Nov 2018 to 1 Feb 2020.
- 13 Feb 2018 Planned primary completion date changed from 22 Feb 2018 to 30 Nov 2019.